Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

FOXM1 predicts disease progression in non-muscle invasive bladder cancer.

Rinaldetti S, Wirtz R, Worst TS, Hartmann A, Breyer J, Dyrskjot L, Erben P.

J Cancer Res Clin Oncol. 2018 Sep;144(9):1701-1709. doi: 10.1007/s00432-018-2694-5. Epub 2018 Jun 29.

PMID:
29959570
2.

Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening.

Rinaldetti S, Rempel E, Worst TS, Eckstein M, Steidler A, Weiss CA, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2018 May 25;9(40):25935-25945. doi: 10.18632/oncotarget.25407. eCollection 2018 May 25.

3.

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2018 Feb 19;9(19):15001-15014. doi: 10.18632/oncotarget.24531. eCollection 2018 Mar 13.

4.

High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.

Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W; Bladder Cancer Research Initiative for Drug Targets Germany (BRIDGE) Consortium eV, Mannheim, Germany.

Clin Genitourin Cancer. 2018 Aug;16(4):248-256.e2. doi: 10.1016/j.clgc.2018.01.009. Epub 2018 Feb 2.

PMID:
29525349
5.

Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.

Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P.

Transl Oncol. 2018 Apr;11(2):467-476. doi: 10.1016/j.tranon.2018.02.001. Epub 2018 Feb 23.

6.

Decreased Invasion of Urothelial Carcinoma of the Bladder by Inhibition of Matrix-Metalloproteinase 7.

Bolenz C, Knauf D, John A, Erben P, Steidler A, Schneider SW, Günes C, Gorzelanny C.

Bladder Cancer. 2018 Jan 20;4(1):67-75. doi: 10.3233/BLC-170124.

7.

High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.

Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A.

Cancer Immunol Immunother. 2018 Mar;67(3):403-412. doi: 10.1007/s00262-017-2093-9. Epub 2017 Nov 17.

PMID:
29150702
8.

Impact of Altered WNT2B Expression on Bladder Wall Fibroblasts: Implications for Apoptosis Regulation in the Stroma of the Lower Urinary Tract.

Worst TS, Daskalova K, Steidler A, Berner-Leischner K, Röth R, Niesler B, Kriegmair MC, Erben P, Pfalzgraf D.

Urol Int. 2017;99(4):476-483. doi: 10.1159/000481440. Epub 2017 Oct 31.

PMID:
29131138
9.

Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies.

Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A.

Oncotarget. 2017 Jun 28;8(40):67684-67695. doi: 10.18632/oncotarget.18804. eCollection 2017 Sep 15.

10.

The EEF1A2 gene expression as risk predictor in localized prostate cancer.

Worst TS, Waldbillig F, Abdelhadi A, Weis CA, Gottschalt M, Steidler A, von Hardenberg J, Michel MS, Erben P.

BMC Urol. 2017 Sep 18;17(1):86. doi: 10.1186/s12894-017-0278-3.

11.

[Role of the human ErbB family receptors in urothelial carcinoma of the bladder: mRNA expression status and prognostic relevance].

Erben P, Wezel F, Wirtz R, Martini T, Stein D, Weis CA, Hartmann A, Bolenz C.

Aktuelle Urol. 2017 Aug;48(4):356-362. doi: 10.1055/s-0043-110403. Epub 2017 Jul 27. German.

PMID:
28750448
12.

Novel insights into a reputably irreversible process: combined mRNA and miRNA profiling of tissue from vesicourethral anastomotic stenosis after radical prostatectomy.

Worst TS, Daskalova K, Steidler A, Berner-Leischner K, Röth R, Niesler B, Weis CA, Kriegmair MC, Erben P, Pfalzgraf D.

World J Urol. 2017 Nov;35(11):1701-1711. doi: 10.1007/s00345-017-2060-2. Epub 2017 Jun 20.

PMID:
28634911
13.

FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes.

Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA, Breyer J, Otto W, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2017 Jul 18;8(29):47595-47606. doi: 10.18632/oncotarget.17394.

14.

Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker.

Worst TS, von Hardenberg J, Gross JC, Erben P, Schnölzer M, Hausser I, Bugert P, Michel MS, Boutros M.

Mol Cell Proteomics. 2017 Jun;16(6):998-1008. doi: 10.1074/mcp.M117.068577. Epub 2017 Apr 9.

15.

High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.

Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stöhr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W.

Transl Oncol. 2017 Jun;10(3):340-345. doi: 10.1016/j.tranon.2017.01.013. Epub 2017 Mar 22.

16.

RAB27A, RAB27B and VPS36 are downregulated in advanced prostate cancer and show functional relevance in prostate cancer cells.

Worst TS, Meyer Y, Gottschalt M, Weis CA, von Hardenberg J, Frank C, Steidler A, Michel MS, Erben P.

Int J Oncol. 2017 Mar;50(3):920-932. doi: 10.3892/ijo.2017.3872. Epub 2017 Feb 10.

PMID:
28197629
17.

In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.

Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium.

Virchows Arch. 2017 Mar;470(3):267-274. doi: 10.1007/s00428-017-2064-8. Epub 2017 Jan 10.

PMID:
28074276
18.

ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.

Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium.

Urol Int. 2017;98(3):282-289. doi: 10.1159/000453670. Epub 2016 Dec 17.

PMID:
27992871
19.

Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.

Kriegmair MC, Balk M, Wirtz R, Steidler A, Weis CA, Breyer J, Hartmann A, Bolenz C, Erben P.

Anticancer Res. 2016 Oct;36(10):5205-5213.

PMID:
27798881
20.

ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).

Breyer J, Wirtz RM, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A, Otto W.

Virchows Arch. 2016 Nov;469(5):547-552. Epub 2016 Aug 11.

PMID:
27514658
21.

Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer.

Kripp M, Merx K, Wirtz RM, Gaiser T, Eidt S, Schwaab J, Post S, Wenz F, Hochhaus A, Hofheinz RD, Erben P.

Gastroenterol Res Pract. 2016;2016:3481578. doi: 10.1155/2016/3481578. Epub 2016 Aug 16.

22.

Lapatinib-induced mesenchymal-epithelial transition in squamous cell carcinoma cells correlates with unexpected alteration of β-catenin expression.

Umbreit C, Erben P, Faber A, Hofheinz RD, Schultz JD, Hoermann K, Wenzel A.

Oncol Lett. 2016 Apr;11(4):2715-2724. Epub 2016 Mar 1.

23.

Low cytoplasmic and nuclear KPNA2 expression in radiotherapy-treated head and neck squamous cell cancer is associated with an adverse outcome.

Erben PB, Brunner K, Hecht M, Haderlein M, Büttner-Herold M, Agaimy A, Fietkau R, Hartmann A, Distel LV.

Int J Clin Exp Pathol. 2015 Dec 1;8(12):15814-24. eCollection 2015.

24.

Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine.

Wezel F, Erben P, Gaiser T, Budjan J, von Hardenberg J, Michel MS, Bolenz C.

Urol Int. 2018;100(1):122-125. doi: 10.1159/000443280. Epub 2016 Jan 19.

PMID:
26780095
25.

MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro.

Umbreit C, Erben P, Faber A, Hofheinz RD, Aderhold C, Weiss C, Hoermann K, Wenzel A, Schultz JD.

Anticancer Res. 2015 Jul;35(7):3801-10.

PMID:
26124325
26.

[Molecular Characterisation of Urothelial Bladder Cancer: Will it Improve Patient Care?].

Erben P, Hartmann A, Bolenz C.

Aktuelle Urol. 2015 May;46(3):227-35. doi: 10.1055/s-0035-1549992. Epub 2015 Jun 12. Review. German.

PMID:
26077307
27.

Incomplete epithelial-mesenchymal transition in p16-positive squamous cell carcinoma cells correlates with β-catenin expression.

Umbreit C, Flanjak J, Weiss C, Erben P, Aderhold C, Faber A, Stern-Straeter J, Hoermann K, Schultz JD.

Anticancer Res. 2014 Dec;34(12):7061-9.

PMID:
25503133
28.

[Detection of lymphovascular invasion in urothelial carcinoma of the bladder through D2-40 immunostaining].

Martini T, Ströbel P, Steidler A, Petrakopoulou N, Erben P, Bolenz C.

Urologe A. 2015 Jan;54(1):70-5. doi: 10.1007/s00120-014-3646-6. German.

PMID:
25391439
29.

IL1RN and KRT13 Expression in Bladder Cancer: Association with Pathologic Characteristics and Smoking Status.

Worst TS, Reiner V, Gabriel U, Weiß C, Erben P, Martini T, Bolenz C.

Adv Urol. 2014;2014:184602. doi: 10.1155/2014/184602. Epub 2014 Jul 8.

30.

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.

Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, Schlegelberger B, Saußele S, Dietz CT, Erben P, Hehlmann R, Hasford J, Hochhaus A, Müller MC.

J Cancer Res Clin Oncol. 2014 Nov;140(11):1965-9. doi: 10.1007/s00432-014-1746-8. Epub 2014 Jun 22.

PMID:
24952896
31.

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.

Haematologica. 2014 Sep;99(9):1441-7. doi: 10.3324/haematol.2013.096537. Epub 2014 May 16.

32.

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.

Leukemia. 2014 Oct;28(10):1988-92. doi: 10.1038/leu.2014.153. Epub 2014 May 6.

PMID:
24798484
33.

Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.

Gosenca D, Kellert B, Metzgeroth G, Haferlach C, Fabarius A, Schwaab J, Kneba M, Scheid C, Töpelt K, Erben P, Haferlach T, Cross NC, Hofmann WK, Seifarth W, Reiter A.

Genes Chromosomes Cancer. 2014 May;53(5):411-21.

PMID:
24772479
34.

Microvascular invasion of testicular nonseminomatous germ cell tumors: implications of separate evaluation of lymphatic and blood vessels.

Heinzelbecker J, Gross-Weege M, Weiss C, Hörner C, Trunk MJ, Erben P, Haecker A, Bolenz C.

J Urol. 2014 Aug;192(2):593-9. doi: 10.1016/j.juro.2014.02.2569. Epub 2014 Mar 12.

PMID:
24631105
35.

MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure.

Agrawal M, Hanfstein B, Erben P, Wolf D, Ernst T, Fabarius A, Saussele S, Purkayastha D, Woodman RC, Hofmann WK, Hehlmann R, Hochhaus A, Müller MC.

Leukemia. 2014 Jul;28(7):1478-85. doi: 10.1038/leu.2014.6. Epub 2014 Jan 10.

PMID:
24472814
36.

The FIP1L1-PDGFRA fusion gene and the KIT D816V mutation are coexisting in a small subset of myeloid/lymphoid neoplasms with eosinophilia.

Schmitt-Graeff AH, Erben P, Schwaab J, Vollmer-Kary B, Metzgeroth G, Sotlar K, Horny HP, Kreipe HH, Fisch P, Reiter A.

Blood. 2014 Jan 23;123(4):595-7. doi: 10.1182/blood-2013-10-530642. No abstract available.

37.

Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML).

Philipp M, Schwaab J, Dietz CT, Hanfstein B, Kalmanti L, Munjal U, Mossner M, Nowak D, Seifarth W, Hofmann WK, Hochhaus A, Müller MC, Erben P.

J Cancer Res Clin Oncol. 2014 Mar;140(3):411-7. doi: 10.1007/s00432-013-1579-x. Epub 2014 Jan 5.

PMID:
24390277
38.

The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.

Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K, Fabarius A, Teichmann M, Schneider S, Ernst T, Müller MC, Giehl M, Marx A, Hartmann K, Hochhaus A, Hofmann WK, Cross NC, Reiter A.

Ann Hematol. 2014 Jan;93(1):81-8. doi: 10.1007/s00277-013-1964-1. Epub 2013 Nov 27.

PMID:
24281161
39.

Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.

Hochhaus A, le Coutre PD, Kantarjian HM, Baccarani M, Erben P, Reiter A, McCulloch T, Fan X, Novick S, Giles FJ.

J Cancer Res Clin Oncol. 2013 Dec;139(12):1985-93. doi: 10.1007/s00432-013-1529-7. Epub 2013 Sep 22.

40.

Comprehensive mutational profiling in advanced systemic mastocytosis.

Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NC, Reiter A.

Blood. 2013 Oct 3;122(14):2460-6. doi: 10.1182/blood-2013-04-496448. Epub 2013 Aug 19.

41.

Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.

Aderhold C, Umbreit C, Faber A, Sauter A, Sommer JU, Birk R, Erben P, Hofheinz RD, Stern-Straeter J, Hörmann K, Schultz JD.

Anticancer Res. 2013 May;33(5):1951-61.

PMID:
23645743
42.

Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib.

La Rosée P, Martiat P, Leitner A, Klag T, Müller MC, Erben P, Schenk T, Saussele S, Hochhaus A.

Ann Hematol. 2013 Oct;92(10):1345-50. doi: 10.1007/s00277-013-1769-2. Epub 2013 Apr 28.

PMID:
23625298
43.

Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study.

Merx K, Fabarius A, Erben P, Griesshammer M, Reiter A, Hofmann WK, Hehlmann R, Hochhaus A, Lengfelder E.

Ann Hematol. 2013 Jul;92(7):907-15. doi: 10.1007/s00277-013-1725-1. Epub 2013 Mar 24.

PMID:
23525684
44.

Molecular analysis of desmoid tumors with a high-density single-nucleotide polymorphism array identifies new molecular candidate lesions.

Erben P, Nowak D, Sauer C, Ströbel P, Hofmann WK, Hofheinz RD, Hohenberger P, Kasper B.

Onkologie. 2012;35(11):684-9. doi: 10.1159/000343744. Epub 2012 Oct 22.

PMID:
23147545
45.

HERV-E-mediated modulation of PLA2G4A transcription in urothelial carcinoma.

Gosenca D, Gabriel U, Steidler A, Mayer J, Diem O, Erben P, Fabarius A, Leib-Mösch C, Hofmann WK, Seifarth W.

PLoS One. 2012;7(11):e49341. doi: 10.1371/journal.pone.0049341. Epub 2012 Nov 7.

46.

Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.

Lengfelder E, Hanfstein B, Haferlach C, Braess J, Krug U, Spiekermann K, Haferlach T, Kreuzer KA, Serve H, Horst HA, Schnittger S, Aul C, Schultheis B, Erben P, Schneider S, Müller-Tidow C, Wörmann B, Berdel WE, Sauerland C, Heinecke A, Hehlmann R, Hofmann WK, Hiddemann W, Büchner T; German Acute Myeloid Leukemia Cooperative Group (AMLCG).

Ann Hematol. 2013 Jan;92(1):41-52. doi: 10.1007/s00277-012-1597-9. Epub 2012 Oct 23.

47.

Activating CBL mutations are associated with a distinct MDS/MPN phenotype.

Schwaab J, Ernst T, Erben P, Rinke J, Schnittger S, Ströbel P, Metzgeroth G, Mossner M, Haferlach T, Cross NC, Hochhaus A, Hofmann WK, Reiter A.

Ann Hematol. 2012 Nov;91(11):1713-20. doi: 10.1007/s00277-012-1521-3. Epub 2012 Aug 10.

PMID:
23010802
48.

Alteration of MMP-2 and -14 expression by imatinib in HPV-positive and -negative squamous cell carcinoma.

Faber A, Sauter A, Hoedt S, Hoermann K, Erben P, Hofheinz RD, Sommer U, Stern-Straeter J, Schultz DJ.

Oncol Rep. 2012 Jul;28(1):172-8. doi: 10.3892/or.2012.1766. Epub 2012 Apr 20.

PMID:
22576800
49.

SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3.

Nowak D, Klaumuenzer M, Hanfstein B, Mossner M, Nolte F, Nowak V, Oblaender J, Hecht A, Hütter G, Ogawa S, Kohlmann A, Haferlach C, Schlegelberger B, Braess J, Seifarth W, Fabarius A, Erben P, Saussele S, Müller MC, Reiter A, Buechner T, Weiss C, Hofmann WK, Lengfelder E.

Genes Chromosomes Cancer. 2012 Aug;51(8):756-67. doi: 10.1002/gcc.21961. Epub 2012 Apr 9.

PMID:
22488577
50.

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Göhring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hänel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saußele S, Hochhaus A; SAKK; German CML Study Group.

Leukemia. 2012 Sep;26(9):2096-102. doi: 10.1038/leu.2012.85. Epub 2012 Mar 26.

PMID:
22446502

Supplemental Content

Support Center